Last reviewed · How we verify
Ropivacaine Hydrocloride
Ropivacaine Hydrocloride is a Local anesthetic (amide) Small molecule drug developed by Women's Hospital HUS. It is currently FDA-approved for Local and regional anesthesia for surgical procedures, Acute pain management via peripheral nerve blocks, Epidural anesthesia. Also known as: 0.2% ropivacaine.
Ropivacaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Ropivacaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for surgical procedures, Acute pain management via peripheral nerve blocks, Epidural anesthesia.
At a glance
| Generic name | Ropivacaine Hydrocloride |
|---|---|
| Also known as | 0.2% ropivacaine |
| Sponsor | Women's Hospital HUS |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
As an amide-type local anesthetic, ropivacaine selectively inhibits sodium influx into nerve fibers, which stabilizes the neuronal membrane and prevents depolarization. This action reversibly blocks pain signal transmission along peripheral nerves. Ropivacaine is structurally similar to bupivacaine but has a lower propensity for cardiotoxicity and central nervous system toxicity.
Approved indications
- Local and regional anesthesia for surgical procedures
- Acute pain management via peripheral nerve blocks
- Epidural anesthesia
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Headache
- Dizziness
- Neurological toxicity (at high doses)
Key clinical trials
- SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty (NA)
- Parturient Satisfaction With Epidural Analgesia by PCEA or Manual Boluses
- QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine Hydrocloride CI brief — competitive landscape report
- Ropivacaine Hydrocloride updates RSS · CI watch RSS
- Women's Hospital HUS portfolio CI
Frequently asked questions about Ropivacaine Hydrocloride
What is Ropivacaine Hydrocloride?
How does Ropivacaine Hydrocloride work?
What is Ropivacaine Hydrocloride used for?
Who makes Ropivacaine Hydrocloride?
Is Ropivacaine Hydrocloride also known as anything else?
What drug class is Ropivacaine Hydrocloride in?
What development phase is Ropivacaine Hydrocloride in?
What are the side effects of Ropivacaine Hydrocloride?
What does Ropivacaine Hydrocloride target?
Related
- Drug class: All Local anesthetic (amide) drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Women's Hospital HUS — full pipeline
- Therapeutic area: All drugs in Anesthesia/Pain Management
- Indication: Drugs for Local and regional anesthesia for surgical procedures
- Indication: Drugs for Acute pain management via peripheral nerve blocks
- Indication: Drugs for Epidural anesthesia
- Also known as: 0.2% ropivacaine
- Compare: Ropivacaine Hydrocloride vs similar drugs
- Pricing: Ropivacaine Hydrocloride cost, discount & access